Bauer Thomas R, Adler Rima L, Hickstein Dennis D
Experimental Transplantation and Immunology Branch of the Center for Cancer Research at the National Cancer Institute of the National Institutes of Health in Bethesda, Maryland 20892, USA.
ILAR J. 2009;50(2):168-86. doi: 10.1093/ilar.50.2.168.
Genetic mutations involving the cellular components of the hematopoietic system--red blood cells, white blood cells, and platelets--manifest clinically as anemia, infection, and bleeding. Although gene targeting has recapitulated many of these diseases in mice, these murine homologues are limited as translational models by their small size and brief life span as well as the fact that mutations induced by gene targeting do not always faithfully reflect the clinical manifestations of such mutations in humans. Many of these limitations can be overcome by identifying large animals with genetic diseases of the hematopoietic system corresponding to their human disease counterparts. In this article, we describe human diseases of the cellular components of the hematopoietic system that have counterparts in large animal species, in most cases carrying mutations in the same gene (CD18 in leukocyte adhesion deficiency) or genes in interacting proteins (DNA cross-link repair 1C protein and protein kinase, DNA-activated catalytic polypeptide in radiation-sensitive severe combined immunodeficiency). Furthermore, we describe the potential of these animal models to serve as disease-specific preclinical models for testing the efficacy and safety of clinical interventions such as hematopoietic stem cell transplantation or gene therapy before their use in humans with the corresponding disease.
涉及造血系统细胞成分(红细胞、白细胞和血小板)的基因突变,在临床上表现为贫血、感染和出血。尽管基因打靶已在小鼠中重现了许多此类疾病,但这些小鼠同源物作为转化模型存在局限性,因为它们体型小、寿命短,而且基因打靶诱导的突变并不总是能如实地反映此类突变在人类中的临床表现。通过鉴定患有与人类疾病相对应的造血系统遗传疾病的大型动物,可以克服其中许多局限性。在本文中,我们描述了造血系统细胞成分的人类疾病,这些疾病在大型动物物种中有对应物,在大多数情况下,这些对应物在同一基因(白细胞黏附缺陷中的CD18)或相互作用蛋白中的基因(辐射敏感严重联合免疫缺陷中的DNA交联修复1C蛋白和DNA激活催化多肽蛋白激酶)中携带突变。此外,我们描述了这些动物模型作为疾病特异性临床前模型的潜力,用于在将造血干细胞移植或基因治疗等临床干预措施应用于患有相应疾病的人类之前,测试其疗效和安全性。